TABLE 3.

Effects of baseline and pharmacologic characteristics on HIV-1 RNA change from baseline among all patients and patients with three or more baseline protease inhibitor mutations^a

Variable	All patients		Patients with three or more PI mutations
	P (simple linear regression)	P (multiple linear regression)	P (simple linear regression)	P (multiple linear regression)
No. of LPV mutations	0.001	ns	0.25
LPV Cmin	0.47		0.06	ns
Log10 LPV GIQ	0.001	0.008	0.03	0.04
Baseline HIV-1 RNA	0.10	0.04	0.32
Baseline CD4 count	0.59		0.29
No. of prior PIs	0.004	0.04	0.17
No. of active NRTIs	0.17		0.46
NNRTI use in an NNRTI-naive patient	0.05	ns	0.06	0.09
CDC class C status	0.27		0.18
Gender	0.58		0.36
Age	0.05	ns	0.56

^aPI, protease inhibitor; LPV, lopinavir; GIQ, genotypic inhibitory quotient; NRTI; nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; ns, not significant.